R 333
Alternative Names: R333Latest Information Update: 29 Oct 2013
At a glance
- Originator Rigel Pharmaceuticals
- Class Small molecules
- Mechanism of Action Janus kinase 3 inhibitors; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Discoid lupus erythematosus
Most Recent Events
- 24 Oct 2013 Discontinued - Phase-II for Discoid lupus erythematosus in Canada (Topical)
- 24 Oct 2013 Discontinued - Phase-II for Discoid lupus erythematosus in USA (Topical)
- 17 Aug 2012 Phase-II clinical trials in Discoid lupus erythematosus in Canada (Topical)